WuXi Biologics (Cayman) Inc. (2269.HK)
| Previous Close | 40.750 |
| Open | 40.350 |
| Bid | 41.500 x 0 |
| Ask | 41.550 x 0 |
| Day's Range | 39.800 - 41.700 |
| 52 Week Range | 35.000 - 77.400 |
| Volume | |
| Avg. Volume | 17,839,821 |
| Market Cap | 176.314B |
| Beta (5Y Monthly) | 1.23 |
| PE Ratio (TTM) | 41.92 |
| EPS (TTM) | 0.990 |
| Earnings Date | Aug 23, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 81.61 |
CNW GroupWuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner Amicus Therapeutics ("Amicus") (Nasdaq: FOLD) on receiving European Commission's approval for Pombiliti™ (cipaglucosidase alfa), a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD).
- Thomson Reuters StreetEvents
Q4 2022 Amicus Therapeutics Inc Earnings Call
Q4 2022 Amicus Therapeutics Inc Earnings Call
CNW GroupWuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a license agreement with GSK plc (LSE/NYSE: GSK) under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms.
